Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

12.07
-0.4300-3.44%
Post-market: 12.070.00000.00%19:30 EDT
Volume:1.03M
Turnover:12.58M
Market Cap:1.25B
PE:-8.93
High:12.79
Open:12.64
Low:12.01
Close:12.50
52wk High:14.93
52wk Low:7.23
Shares:103.52M
Float Shares:88.69M
Volume Ratio:0.84
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3513
EPS(LYR):-1.4747
ROE:-39.80%
ROA:-25.97%
PB:3.28
PE(LYR):-8.18

Loading ...

Oric Pharma Grants 39,200 Stock Options, 6,400 RSUs to New Employees Under Inducement Plan

Reuters
·
Sep 05

Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 05

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Sep 05

Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial

TIPRANKS
·
Sep 04

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 03

Oric Pharma CFO Dominic Piscitelli Disposes of 77,000 Common Shares Worth $1.05 Million

Reuters
·
Aug 29

Pharscin Pharmaceutical Receives Clinical Trial Approval for Glaucoma Eye Drop Candidate

Stock News
·
Aug 13

Oric Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Janux Therapeutics Inc (JANX) and Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Aug 10

Oric Pharma Grants 125,400 Stock Options, 20,550 RSUs to Five New Employees

Reuters
·
Aug 08

Oric Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
Aug 04

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

TIPRANKS
·
Aug 04

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

TIPRANKS
·
Aug 04

Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38

THOMSON REUTERS
·
Aug 04

ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate

Benzinga Earnings
·
Aug 04

Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC

Reuters
·
Aug 04

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

GlobeNewswire
·
Aug 04

Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares

Reuters
·
Jul 31